Imcera Group Inc. on Thursday said its Pitman-Moore animalhealth care unit has agreed to collaborate with CambridgeBiotech Corp. on a Lyme disease vaccine for dogs and on otheranimal health programs,
Pitman-Moore of Lake Forest, Ill., will acquire rights to theWorchester, Mass., company's existing Lyme disease programand the right to use Cambridge's patented adjuvant technology."They can evaluate (the adjuvant) in various vaccines underdevelopment," Cambridge spokeswoman Christina Pappas toldBioWorld.
Pitman-Moore already uses the adjuvant in its feline leukemiavaccine, which was developed by Cambridge.
The adjuvant is also in preclinical studies of a malaria vaccineand as an immunotherapeutic in certain cancers.
The companies have not yet discussed marketing arrangementsfor any products that may arise from the collaboration sincethe products are still a long way off, Pappas said. Financialterms were not disclosed.
Cambridge stock (NASDAQ:CBCX) closed up $1 at $11 onMonday. -- RF
(c) 1997 American Health Consultants. All rights reserved.